Apar Kishor Ganti, MD, on SCLC: Comparing Quality of Life With Once- and Twice-Daily Thoracic Radiotherapy
2022 ASCO Annual Meeting
Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses results from the CALGB 30610 study, which showed a similar clinical benefit for once- and twice-daily radiotherapy administered to patients with limited-stage small cell lung cancer. While both regimens were well tolerated, patients who received radiotherapy once daily had better quality-of-life scores at week 3 and slightly worse scores at week 12. Patients believed the once-daily regimen was more convenient (Abstract 8504).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
CLGB 30610 was a randomized phase three trial that looked at two different radiation regimens for patients with limited state small cell lung cancer. The trial randomized 646 patients to either twice a day radiation, to 45 gray or once a day radiation to 70 gray in combination with chemotherapy. The results of that trial showed that both arms were similar in terms of overall survival.
Since there was no significant difference in outcomes between the two arms, it becomes important to look at other measures to determine what patients should be treated with. This was a quality of life study, as that was conducted as part of CLGB 30610. And what we did, was we selected... we invited a group of individuals who were randomized to the study to take part in the quality of life sub-study. 417 patients agreed to participate in the study and the data includes 338 patients who had the baseline questionnaires completed and at least one follow up questionnaire that was completed.
Overall, the compliance rate was very good with almost 71% of patients completing the questionnaires at week 52. What we found was that in general, both regiments were well tolerated. However, there were some differences which are not surprising considering the radiation schedules. The once a day radiation regimen was better tolerated and had better quality of life scores at three weeks. Whereas the twice a day regimen was better when we looked at the same scores at the 12 week interval. At the end of the year, there were not significant differences between the two groups.
When we looked at acute esophagitis and difficulty in swallowing, the twice a day regimen was worse at week three, but the once a day regimen was slightly worse at week 12. Again, this is not surprising since the majority of the radiation is completed by the end of week three in the twice a day regimen. And the once a day regimen takes almost seven weeks to complete. So the swallowing difficulties were later in the once a day regimen.
However, at the end of one year, there was not a significant difference between the two arms. When we looked at global quality of life. Again, those results mimic what we saw with the swallowing. The twice a day arm did worse at week three, but the once a day arm was slightly worse at week 12, we then asked patients to see, to let us know which regimen was more convenient. We asked them to grade the convenience to very inconvenient, moderately inconvenient, moderately convenient, or very convenient. And while there were some differences, those differences were not statistically significant.
And we then combined the two inconvenient groups and label them as inconvenient and the two convenient groups and combined them into one group called convenient. We found a statistically significant difference. About 67% of patients felt that twice a day regimen was convenient as opposed to 75% of patients who felt that once a day regimen was convenient. This difference was statistically significant.
So in summary, while there was no difference in overall outcomes in between the two regiments, the once a day regimen and the twice a day regimen, there were some differences in the quality of life scores, with the once a day regimen being better at three weeks and the twice a day regimen being better at about 12 weeks. The most important finding was that patients found that the once a day regimen was more convenient than the twice a day regimen. And we believe that the once a day regimen will be the new standard of care based on this.
Related Videos
The ASCO Post Staff
Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low rates of local tumor recurrence at 5 years. These patients, the research suggests, may be able to forgo radiotherapy (Abstract LBA501).
The ASCO Post Staff
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, compared with nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer. A phase III trial comparing intermittent relacorilant plus nab-paclitaxel with investigator’s choice of chemotherapy in primary platinum-refractory disease is ongoing (Abstract LBA5503).
The ASCO Post Staff
Bradley J. Monk, MD, of the University of Arizona College of Medicine and Creighton University School of Medicine, discusses phase III findings from the ATHENA–MONO (GOG-3020/ENGOT-ov45) trial. It showed that rucaparib as first-line maintenance treatment, following first-line platinum-based chemotherapy, improved progression-free survival in patients with ovarian cancer, irrespective of homologous recombination deficiency status (Abstract LBA5500).
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III findings from the DETERMINATION trial, which showed that, for patients with newly diagnosed multiple myeloma, lenalidomide, bortezomib, and dexamethasone (RVd) with or without autologous stem cell transplant (ASCT) and lenalidomide maintenance to disease progression resulted in the longest median progression-free survival reported for each approach, and a highly significant difference in progression-free survival in favor of early transplant. While overall response rates were similar, rates of MRD favored early transplant also, but toxicity was greater and quality of life was transiently but significantly diminished. No overall survival advantage has been observed to date (Abstract LBA4).
The ASCO Post Staff
Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discuss phase III results from the ASCEMBL trial, which showed that after more than 2 years of follow-up, asciminib continued to yield superior efficacy and better safety and tolerability vs bosutinib in patients with chronic myeloid leukemia (CML) in chronic phase. These results continue to support the use of this kinase inhibitor as a new CML therapy, says Dr. Cortes, with the potential to transform the standard of care (Abstract 7004).
